Exozymes Inc Quick Ratio (EXOZ) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Exozymes Inc   (NASDAQ: EXOZ)

Exozymes Inc 's Quick Ratio

EXOZ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Exozymes Inc 's Cash & cash equivalent grew by 291.31 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Exozymes Inc 's Quick Ratio to 3.49, above Exozymes Inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 73 other companies have achieved higher Quick Ratio than Exozymes Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1009, from total ranking in the first quarter 2026 at 1609.

Explain Quick Ratio?
How much Cash & cash equivalents EXOZ´s has?
What are EXOZ´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EXOZ Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 32.96 % 9.56 % 17.53 % -78.66 % 63.3 %
Y / Y Cash & cash equivalent Change -19.08 % -83.03 % -68.73 % 2079.53 % 10405.05 %
Quick Ratio MRQ 3.49 0.91 1.94 4.12 5.74
EXOZ's Total Ranking # 1009 # 1609 # 1188 # 642 # 419
Seq. Current Liabilities Change 2.25 % 0.99 % 26.53 % 1.77 % -15.74 %
Seq. Cash & cash equivalent Change 291.31 % -52.47 % -40.39 % -27.01 % -17.92 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 74
Healthcare Sector # 374
Overall Market # 1009


Quick Ratio Statistics
High Average Low
7.29 3.28 0.04
(Dec 31 2024)   (Sep 30 2024)




Financial Statements
Exozymes Inc 's Current Liabilities $ 2 Millions Visit EXOZ's Balance sheet
Exozymes Inc 's Cash & cash equivalent $ 6 Millions Visit EXOZ's Balance sheet
Source of EXOZ's Sales Visit EXOZ's Sales by Geography


Cumulative Exozymes Inc 's Quick Ratio

EXOZ's Quick Ratio for the trailling 12 Months

EXOZ Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -38.7 % -39.9 % -30.63 % -20.08 % 1214.64 %
Y / Y Cash & cash equivalent TTM Growth -40.14 % -10.59 % 135.89 % 9990.48 % 38171.55 %
Quick Ratio TTM 2.54 2.96 4.32 5.79 2.6
Total Ranking TTM # 3766 # 3783 # 2812 # 2747 # 2625
Seq. Current Liabilities TTM Growth 7.16 % 2.53 % 4.47 % -46.59 % 5.06 %
Seq. Cash & cash equivalent TTM Growth -8.05 % -29.9 % -22.03 % 19.11 % 37.34 %

Quick ratio ranking by company, industry and sector >> Back to EXOZ Financial Strength Comparisons >> Go to Compare EXOZ Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $1.62 millions, cumulative Quick Ratio decreased to 2.54 below the Exozymes Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Exozymes Inc . While Quick Ratio overall ranking has improved so far to 3766, from total ranking during the twelve months ending first quarter 2026 at 3783.

Explain Quick Ratio?
How much Cash & cash equivalents EXOZ´s has?
What are EXOZ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 140
Healthcare Sector # 876
Within the Market # 3766


trailing twelve months Quick Ratio Statistics
High Average Low
5.79 3.32 1.69
(Sep 30 2025)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Eikon Therapeutics Inc   9.61 $ 531.178  Millions$ 55.296  Millions
Zura Bio Limited  9.46 $ 205.134  Millions$ 21.690  Millions
4d Molecular Therapeutics Inc   9.16 $ 436.624  Millions$ 47.673  Millions
Fate Therapeutics Inc   8.44 $ 275.141  Millions$ 32.592  Millions
Monte Rosa Therapeutics Inc   8.32 $ 1,152.100  Millions$ 138.548  Millions
Cullinan Therapeutics Inc   8.23 $ 334.500  Millions$ 40.628  Millions
Prokidney Corp   7.99 $ 181.564  Millions$ 22.710  Millions
In8bio Inc   7.97 $ 17.956  Millions$ 2.254  Millions
Denali Therapeutics Inc   7.89 $ 710.471  Millions$ 90.083  Millions
Redwoods Acquisition Corp  7.69 $ 9.300  Millions$ 1.210  Millions
Cardiff Oncology Inc   7.04 $ 76.005  Millions$ 10.797  Millions
Black Diamond Therapeutics Inc   6.98 $ 110.506  Millions$ 15.843  Millions
Immunovant Inc   6.81 $ 797.798  Millions$ 117.102  Millions
Scholar Rock Holding Corp  6.81 $ 492.088  Millions$ 72.242  Millions
Fennec Pharmaceuticals Inc   6.66 $ 82.498  Millions$ 12.394  Millions
Krystal Biotech Inc   6.64 $ 845.600  Millions$ 127.397  Millions
Caribou Biosciences Inc   6.33 $ 113.800  Millions$ 17.974  Millions
Cognition Therapeutics inc   6.24 $ 34.012  Millions$ 5.450  Millions
C4 Therapeutics Inc   6.24 $ 300.854  Millions$ 48.247  Millions
Repligen Corp  5.94 $ 810.449  Millions$ 136.403  Millions
Cabaletta Bio Inc   5.64 $ 225.101  Millions$ 39.910  Millions
Revolution Medicines Inc   5.54 $ 3,937.969  Millions$ 710.589  Millions
Humacyte Inc   5.35 $ 79.903  Millions$ 14.948  Millions
Invivyd Inc   5.16 $ 160.080  Millions$ 31.028  Millions
Lineage Cell Therapeutics Inc   5.13 $ 50.855  Millions$ 9.914  Millions
Alector Inc   5.05 $ 172.798  Millions$ 34.236  Millions
Atyr Pharma Inc   5.04 $ 57.418  Millions$ 11.396  Millions
Vericel Corporation  5.04 $ 264.531  Millions$ 52.532  Millions
Inhibrx Biosciences Inc   4.75 $ 133.344  Millions$ 28.064  Millions
Replimune Group Inc   4.57 $ 195.328  Millions$ 42.767  Millions

Date modified: 2026-09-08T17:40:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.